Literature DB >> 11211178

A human CD46 transgenic pig model system for the study of discordant xenotransplantation.

L E Diamond1, C M Quinn, M J Martin, J Lawson, J L Platt, J S Logan.   

Abstract

BACKGROUND: The chronic shortage in the supply of human organs available for allotransplantation has turned attention toward the use of animals as potential donors, with pigs as the most likely species under consideration. Hyperacute rejection, the initial and immediate barrier to a pig-to-primate xenograft, has been addressed by generation of transgenic pigs that express the human membrane-bound complement-regulatory proteins CD59 and/or CD55. Difficulty has been encountered in generation of transgenic animals that express a third membrane-bound complement-regulatory protein, CD46.
METHODS: We have generated transgenic animals by using a large genomic construct that encompasses the entire human CD46 gene.
RESULTS: We report the first description of transgenic mice and pigs that express high levels of human CD46 in a cell and tissue type-specific manner, resembling patterns of endogenous CD46 expression observed in human tissues. Furthermore, when human CD46 transgenic porcine hearts were transplanted into baboons, the grafts did not succumb to hyperacute rejection, and survival extended for up to 23 days. Under the same conditions, nontransgenic grafts underwent hyperacute rejection within 90 min.
CONCLUSIONS: This is the first report to describe generation of transgenic pigs that express human CD46, and the first in vivo demonstration of the ability of human CD46 expressed on pig organs to regulate complement activation and overcome hyperacute rejection upon transplantation of a vascularized organ into nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11211178     DOI: 10.1097/00007890-200101150-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  40 in total

Review 1.  Genetic modification of xenografts.

Authors:  J L Platt
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

Review 2.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 3.  Interspecies chimeric complementation for the generation of functional human tissues and organs in large animal hosts.

Authors:  Jun Wu; Juan Carlos Izpisua Belmonte
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

Review 4.  Animal transgenesis: state of the art and applications.

Authors:  Eduardo O Melo; Aurea M O Canavessi; Mauricio M Franco; Rodolfo Rumpf
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

Review 5.  Accommodation of grafts: implications for health and disease.

Authors:  Amy H Tang; Jeffrey L Platt
Journal:  Hum Immunol       Date:  2007-05-15       Impact factor: 2.850

Review 6.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

Review 7.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 8.  Genetic modifications of pigs for medicine and agriculture.

Authors:  Jeffrey J Whyte; Randall S Prather
Journal:  Mol Reprod Dev       Date:  2011-06-10       Impact factor: 2.609

9.  Expression of human CD46 has no effect on porcine circovirus type 2 infection and shedding in the experimental pig model.

Authors:  Michelle Hemann; Hui-Gang Shen; Nathan M Beach; Xiang-Jin Meng; Patrick G Halbur; Tanja Opriessnig
Journal:  Vet Res Commun       Date:  2012-03-03       Impact factor: 2.459

Review 10.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.